MAGGI, CLAUDIA
 Distribuzione geografica
Continente #
EU - Europa 2.276
NA - Nord America 1.912
AS - Asia 1.583
Continente sconosciuto - Info sul continente non disponibili 206
SA - Sud America 113
AF - Africa 35
OC - Oceania 16
Totale 6.141
Nazione #
US - Stati Uniti d'America 1.842
DE - Germania 1.064
CN - Cina 494
GB - Regno Unito 439
SG - Singapore 407
IT - Italia 245
BD - Bangladesh 228
SE - Svezia 159
HK - Hong Kong 138
VN - Vietnam 126
RU - Federazione Russa 95
BR - Brasile 84
FR - Francia 70
NL - Olanda 58
CA - Canada 54
IE - Irlanda 42
FI - Finlandia 38
IN - India 38
ID - Indonesia 29
JP - Giappone 24
TR - Turchia 23
KR - Corea 19
AU - Australia 16
UA - Ucraina 14
CI - Costa d'Avorio 11
BE - Belgio 10
PL - Polonia 10
AR - Argentina 9
IQ - Iraq 9
TH - Thailandia 9
MX - Messico 7
DK - Danimarca 6
AT - Austria 5
CO - Colombia 5
EC - Ecuador 5
ES - Italia 5
KE - Kenya 5
IR - Iran 4
JO - Giordania 4
PK - Pakistan 4
SA - Arabia Saudita 4
UZ - Uzbekistan 4
CH - Svizzera 3
DZ - Algeria 3
MA - Marocco 3
TW - Taiwan 3
VE - Venezuela 3
ZA - Sudafrica 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BO - Bolivia 2
CL - Cile 2
EG - Egitto 2
EU - Europa 2
GR - Grecia 2
IL - Israele 2
JM - Giamaica 2
KG - Kirghizistan 2
NP - Nepal 2
PT - Portogallo 2
SN - Senegal 2
TT - Trinidad e Tobago 2
AM - Armenia 1
BG - Bulgaria 1
BH - Bahrain 1
BW - Botswana 1
CG - Congo 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
HN - Honduras 1
HR - Croazia 1
IS - Islanda 1
KW - Kuwait 1
LT - Lituania 1
LV - Lettonia 1
MY - Malesia 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
PA - Panama 1
PE - Perù 1
PH - Filippine 1
PR - Porto Rico 1
RO - Romania 1
RS - Serbia 1
SC - Seychelles 1
SR - Suriname 1
SV - El Salvador 1
TL - Timor Orientale 1
TN - Tunisia 1
UY - Uruguay 1
Totale 5.937
Città #
Frankfurt am Main 955
Southend 398
Ashburn 246
Singapore 243
Chandler 175
Hong Kong 132
Beijing 105
San Jose 94
Milan 93
Seattle 90
Fairfield 84
Council Bluffs 73
Dallas 63
Los Angeles 56
Wilmington 55
New York 50
Munich 48
Princeton 48
Cambridge 46
Houston 46
Santa Clara 45
Woodbridge 41
Dublin 40
Ho Chi Minh City 38
Phoenix 32
Buffalo 29
Hanoi 29
Lauterbourg 24
Nanjing 23
Ann Arbor 22
Dearborn 22
Moscow 21
Toronto 21
Columbus 20
Guangzhou 20
Boardman 19
Des Moines 19
Jakarta 18
Shanghai 18
Tokyo 18
Istanbul 16
San Diego 16
Shenyang 16
The Dalles 15
Da Nang 14
Eitensheim 14
Bengaluru 13
Naples 13
Zhengzhou 13
Helsinki 12
Jinan 12
Abidjan 11
Chicago 11
Hangzhou 11
Rome 11
Turin 11
Brussels 9
Changsha 9
Nanchang 9
Cangzhou 8
Falls Church 8
Grafing 8
Redwood City 8
Amsterdam 7
Fuzhou 7
Montreal 7
Newark 7
Silver Spring 7
São Paulo 7
Bari 6
Bexley 6
Hebei 6
Stockholm 6
Sydney 6
Taiyuan 6
Tianjin 6
Turku 6
Bangkok 5
Brooklyn 5
Charlotte 5
Düsseldorf 5
Nairobi 5
Orem 5
Warsaw 5
Amman 4
Andover 4
Baghdad 4
Haikou 4
Hefei 4
Jiaxing 4
Kunming 4
Las Vegas 4
Manchester 4
Ningbo 4
Nuremberg 4
Piscataway 4
Rio de Janeiro 4
San Francisco 4
Shenzhen 4
Washington 4
Totale 4.076
Nome #
GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab : A clinical and translational study 354
Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase 353
Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies 326
Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status 326
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer : a Retrospective Comparison of Efficacy and Safety Profiles 298
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan 283
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer 271
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation 261
Single agent panitumumab in kras wild-type metastatic colorectal cancer patients following cetuximab-based regimens 260
FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma 257
Role of cMET in the development and progression of colorectal cancer 252
First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer : a systematic review and meta-analysis 251
TP53 mutations in advanced colorectal cancer : the dark side of the moon 249
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab : a meta-analysis 248
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives 248
Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases 245
Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil : a meta-analysis of published trials 235
Bevacizumab treatment in the elderly patient with metastatic colorectal cancer 226
Role of MGMT as biomarker in colorectal cancer 223
Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer : A systematic review and meta-analysis of published trials 217
Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer : an Italian Trials of Medical Oncology phase II study 214
Treatment of elderly patients with metastatic renal cell carcinoma 192
Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab 185
In reply 167
Totale 6.141
Categoria #
all - tutte 14.204
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.204


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022254 0 10 5 13 20 16 13 13 21 55 13 75
2022/2023508 58 68 55 46 50 85 5 35 77 5 16 8
2023/2024908 4 20 15 8 78 16 137 126 68 156 136 144
2024/20251.066 130 115 101 129 51 28 25 73 39 107 78 190
2025/20261.676 183 86 158 110 149 94 211 45 118 82 261 179
2026/2027233 119 114 0 0 0 0 0 0 0 0 0 0
Totale 6.141